The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB).
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
The Food and Drug Administration (FDA) has, for the first time, approved an artificial intelligence diagnostic device that doesn’t need a specialised doctor to interpret the results.
If people’s explanations of what blockchain is sound like gibberish to you, there is a popular application that shares the philosophy of the blockchain technology that can help you understand how it works: Wikipedia.
French CAR-T specialist Cellectis didn’t have the best time in 2017, but it seems their luck is changing, having just closed a $164 million U.S. public offering.
GlaxoSmithKline Chief Executive, Emma Wamsley is keeping her promise to cut the drugmaker’s pharmaceutical portfolio — the company said today that it is handing its rare disease gene therapy drugs to Orchard Therapeutics.
Helix has announced two new application development deals with PerkinElmer and Northshore University Health System, in an attempt to ease access to genetic disease risk information.
Illumina and Loxo Oncology have announced a global strategic partnership to develop a diagnostic tool that will work with Loxo’s larotrectinib and another of its experimental cancers drugs, across tumour types.
Newly appointed CEO of Novartis, Vas Narasimhan has his sights set on the gene therapy area as the next big development in the pharmaceutical industry.
Patient advocacy groups take in millions from drugmakers. Is there a payback? Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
AstraZeneca has received a double boost for its oncology portfolio after US and European regulators accepted regulatory submissions for its drugs.
Pfizer has revealed this week that it intends to take a 25% stake in Allogene Therapeutics, in order to accelerate the development of CAR-T cell therapies sources from donors instead of patients.